New radiation applicator aims to treat rectal cancer without surgery

NCT ID NCT07402486

Not yet recruiting Disease control Sponsor: Siriraj Hospital Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase II trial tests a new device called the Maastro applicator, which delivers high-dose radiation directly to rectal tumors. The goal is to see if it can safely eliminate the cancer and allow patients to avoid major surgery. Twenty adults with rectal cancer will receive this treatment and be closely monitored for tumor response and side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: High-dose-rate brachytherapy via Maastro applicator (radiation)
What this could lead to: If successful, this could offer a non-surgical treatment option for rectal cancer, potentially avoiding the need for a permanent stoma and reducing complications.
What could go wrong: This is a small, early-phase study with only 20 participants. The treatment may not fully eliminate the tumor, and there is a risk of cancer regrowth. Side effects from radiation are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

rectal cancer rectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RECTAL CANCER

More trials for these conditions

Other studies related to the condition(s) this trial covers.